PRLD · Prelude Therapeutics Incorporated Common Stock
View on chartInsiders & Stakes
| RA CAPITAL MANAGEMENT, L.P. Director | ▼ Sell | Other | 6,475,882 Shares held | 4/27/2026 | View profile |
| Krishna Vaddi President, CEO | ▲ Buy | Open Market | 1,999,296 Shares held | 3/25/2025 | View profile |
| ORBIMED ADVISORS LLC Director | ▲ Buy | Open Market | 1,126,126 Shares held | 4/21/2026 | View profile |
| David P. Bonita Director | ▲ Buy | Open Market | 1,126,126 Shares held | 4/21/2026 | View profile |
| Andrew Combs EVP, Head of Chemistry | ▲ Buy | Open Market | 480,123 Shares held | 3/25/2025 | View profile |
| Scherle Peggy Chief Scientific Officer | ▼ Sell | Open Market | 172,920 Shares held | 8/27/2021 | View profile |
| Jane Huang President, CMO | ▼ Sell | Tax Withholding | 86,917 Shares held | 10/4/2025 | View profile |
| Chardonnet Laurent Chief Financial Officer | ▲ Buy | Open Market | 42,165 Shares held | 5/23/2023 | View profile |
| Lim Bryant David Chief Legal Officer, Corp Sec. | ▲ Buy | Open Market | 27,400 Shares held | 12/19/2024 | View profile |
| Pierce Christopher EVP and Chief of Business Oper | ▼ Sell | Open Market | 3,750 Shares held | 9/2/2021 | View profile |
| Morosini Deborah EVP, Chief of Clinical Affairs | ▼ Sell | Open Market | 444 Shares held | 12/15/2021 | View profile |
| Mauro David J Chief Medical Officer | ▼ Sell | Open Market | 0 Shares held | 10/5/2021 | View profile |
| Piper Brian Chief Financial Officer | ▼ Sell | Open Market | 0 Shares held | 8/25/2021 | View profile |
Transaction History
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 1,407,000 | — | 4/27/2026 |
| David P. Bonita | ▲ Buy | Open Market | 1,689,189 | $7.5M | 4/21/2026 |
| David P. Bonita | ▲ Buy | Open Market | 1,126,126 | $5.0M | 4/21/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,689,189 | $7.5M | 4/21/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,126,126 | $5.0M | 4/21/2026 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 10/4/2025 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,355 | $5K | 10/4/2025 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 7/4/2025 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,355 | $3K | 7/4/2025 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 4/4/2025 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,355 | $2K | 4/4/2025 |
| Andrew Combs | ▲ Buy | Open Market | 100,000 | $69K | 3/25/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 675,000 | $467K | 3/25/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 15,000 | $11K | 3/21/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 5,416 | $4K | 3/20/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 9,106 | $7K | 3/17/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 29,999 | $23K | 3/14/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 50,000 | $36K | 3/13/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 47,500 | $34K | 3/12/2025 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 1/4/2025 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,859 | $5K | 1/4/2025 |
| Krishna Vaddi | ▲ Buy | Open Market | 5,000 | $6K | 12/31/2024 |
| Krishna Vaddi | ▲ Buy | Open Market | 10,000 | $12K | 12/30/2024 |
| Andrew Combs | ▲ Buy | Open Market | 60,000 | $82K | 12/23/2024 |
| Andrew Combs | ▲ Buy | Open Market | 3,075 | $4K | 12/20/2024 |
| Lim Bryant David | ▲ Buy | Open Market | 25,000 | $23K | 12/19/2024 |
| Krishna Vaddi | ▲ Buy | Open Market | 6,888 | $6K | 12/19/2024 |
| Krishna Vaddi | ▲ Buy | Open Market | 100,000 | $93K | 12/18/2024 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 10/4/2024 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,349 | $7K | 10/4/2024 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 7/4/2024 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,347 | $12K | 7/4/2024 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 4/4/2024 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,347 | $16K | 4/4/2024 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 1/4/2024 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,844 | $14K | 1/4/2024 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 10/4/2023 |
| Jane Huang | ▲ Buy | Option Exercise | 9,375 | — | 7/4/2023 |
| Jane Huang | ▼ Sell | Tax Withholding | 3,242 | $15K | 7/4/2023 |
| Krishna Vaddi | ▲ Buy | Open Market | 900 | $5K | 5/25/2023 |
| Krishna Vaddi | ▲ Buy | Open Market | 1,000 | $5K | 5/24/2023 |
| Lim Bryant David | ▲ Buy | Open Market | 2,400 | $13K | 5/24/2023 |
| Chardonnet Laurent | ▲ Buy | Open Market | 5,000 | $28K | 5/23/2023 |
| Krishna Vaddi | ▲ Buy | Open Market | 11,856 | $67K | 5/23/2023 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 869,565 | $5.0M | 5/22/2023 |
| David P. Bonita | ▲ Buy | Open Market | 869,565 | $5.0M | 5/22/2023 |
| Jane Huang | ▼ Sell | Open Market | 13,280 | $81K | 4/6/2023 |
| Jane Huang | ▲ Buy | Option Exercise | 37,500 | — | 4/4/2023 |
| Krishna Vaddi | ▲ Buy | Open Market | 19,188 | $98K | 12/20/2022 |
| Chardonnet Laurent | ▲ Buy | Open Market | 10,000 | $48K | 12/8/2022 |
| Chardonnet Laurent | ▲ Buy | Open Market | 10,000 | $42K | 6/1/2022 |
| Andrew Combs | ▲ Buy | Option Exercise | 36,062 | $68K | 3/31/2022 |
| Chardonnet Laurent | ▲ Buy | Grant | 6,500 | $49K | 3/21/2022 |
| Morosini Deborah | ▲ Buy | Option Exercise | 3,016 | $6K | 12/15/2021 |
| Morosini Deborah | ▲ Buy | Option Exercise | 25,735 | $331K | 12/15/2021 |
| Morosini Deborah | ▼ Sell | Open Market | 28,751 | $374K | 12/15/2021 |
| Andrew Combs | ▲ Buy | Open Market | 4,000 | $46K | 12/14/2021 |
| Andrew Combs | ▲ Buy | Open Market | 4,000 | $48K | 12/13/2021 |
| Chardonnet Laurent | ▲ Buy | Grant | 5,000 | $61K | 12/13/2021 |
| Krishna Vaddi | ▲ Buy | Grant | 8,000 | $97K | 12/13/2021 |
| Morosini Deborah | ▲ Buy | Option Exercise | 28,751 | $369K | 11/16/2021 |
| Morosini Deborah | ▼ Sell | Open Market | 28,351 | $450K | 11/16/2021 |
| Morosini Deborah | ▼ Sell | Open Market | 400 | $7K | 11/16/2021 |
| Mauro David J | ▲ Buy | Option Exercise | 15,000 | $28K | 10/5/2021 |
| Mauro David J | ▼ Sell | Open Market | 5,908 | $179K | 10/5/2021 |
| Mauro David J | ▼ Sell | Open Market | 7,803 | $244K | 10/5/2021 |
| Mauro David J | ▼ Sell | Open Market | 1,289 | $41K | 10/5/2021 |
| Mauro David J | ▲ Buy | Option Exercise | 15,000 | $28K | 9/7/2021 |
| Mauro David J | ▼ Sell | Open Market | 7,487 | $269K | 9/7/2021 |
| Mauro David J | ▼ Sell | Open Market | 2,873 | $106K | 9/7/2021 |
| Mauro David J | ▼ Sell | Open Market | 4,640 | $175K | 9/7/2021 |
| Pierce Christopher | ▲ Buy | Option Exercise | 17,000 | $218K | 9/2/2021 |
| Pierce Christopher | ▼ Sell | Open Market | 3,343 | $135K | 9/2/2021 |
| Pierce Christopher | ▼ Sell | Open Market | 6,727 | $279K | 9/2/2021 |
| Pierce Christopher | ▼ Sell | Open Market | 6,930 | $295K | 9/2/2021 |
| Scherle Peggy | ▲ Buy | Option Exercise | 6,014 | $9K | 8/27/2021 |
| Scherle Peggy | ▼ Sell | Open Market | 2,700 | $95K | 8/27/2021 |
| Scherle Peggy | ▼ Sell | Open Market | 2,707 | $98K | 8/27/2021 |
| Scherle Peggy | ▼ Sell | Open Market | 607 | $23K | 8/27/2021 |
| Scherle Peggy | ▲ Buy | Option Exercise | 1,700 | $2K | 8/26/2021 |
| Scherle Peggy | ▼ Sell | Open Market | 1,700 | $60K | 8/26/2021 |
| Piper Brian | ▼ Sell | Open Market | 2,100 | $68K | 8/25/2021 |
| Piper Brian | ▼ Sell | Open Market | 3,889 | $129K | 8/25/2021 |
| Piper Brian | ▼ Sell | Open Market | 2,344 | $80K | 8/25/2021 |
| Piper Brian | ▲ Buy | Option Exercise | 8,333 | $16K | 8/25/2021 |
| Scherle Peggy | ▲ Buy | Option Exercise | 558 | $1K | 8/13/2021 |
| Scherle Peggy | ▲ Buy | Option Exercise | 1,728 | $2K | 8/13/2021 |
| Scherle Peggy | ▼ Sell | Open Market | 2,286 | $80K | 8/13/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly
Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.